Assessment of the Impact of Repeated Ischemic Preconditioning Episodes on Hemodynamic and Metabolic Parameters in Patients at Various Stages of Chronic Kidney Disease

August 3, 2026 updated by: Katarzyna Peczek-Bartyzel, Medical University of Lodz
The aim of our study is to evaluate the impact of repeated episodes of ischemic quenching on changes in blood pressure, heart rate and laboratory parameters of inflammation in patients with kidney diseases. There is credible evidence that intentionally producing periods of ischemia provides protection of the myocardium and blood vessels against subsequent ischemic injury. The examination will be performed during hospitalization in the Department of Nephrology, Hypertension, Transplantology and Internal Diseases and will last 4 days. On the first day, blood pressure will be measured using an automatic blood pressure monitor, radial artery pulse, blood saturation will be measured using a pulse oximeter, and approximately 6 ml of venous blood will be collected from the elbow bend area for laboratory tests. Then, compression of the lower limb below the knee will be performed using a blood pressure cuff. Four 5-minute cycles of inflation and deflation of the cuff will be performed. The pressure on the lower limb will be repeated on the next two days. On the last day of the examination, blood pressure, heart rate and blood saturation will be measured again, and approximately 6 ml of venous blood will be collected again for laboratory tests.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Michał Nowicki, Professor
  • Phone Number: +48 42 201 44 00
  • Email: nefro@wp.pl

Study Contact Backup

Study Locations

  • Poland
      • Lodz, Poland, 90-213
        • Recruiting
        • Medical University of Lodzi
        • Contact:
        • Contact:
        • Sub-Investigator:
          • Katarzyna Pęczek-Bartyzel, MD Phd
        • Principal Investigator:
          • Michał Nowicki, Professor
      • Lodz, Poland, 92-219
        • Recruiting
        • Medical University of Lodzi
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • obtaining the patient's voluntary, informed consent to participate in the experiment,
  • chronic kidney disease in stages G1-G5,
  • women and men over 18 years of age.
  • failure to meet the qualification criteria for participation in the study,
  • consciousness disorders,
  • heart failure (NYHA IV),
  • severe anemia (Hb concentration<8g/dL),
  • features of muscle cell damage (e.g. rhabdomyolysis),
  • peripheral circulation disorders, peripheral vascular diseases.

Exclusion Criteria:

-

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Chronic hemodialyzed patients
Patients with chronic kidney disease (CKD) G5 during chronic hemodialysis
Other: Preconditioning with control ischemic episodes
4 cycles of 5-minute inflation and deflation using a sphygmomanometer cuff at a pressure of 30 mmHg above the systolic value through three consecutive days
Other: Patient with CKD G1-G5
Patient with CKD G1-G5 without patients during chronic hemodialysis
Other: Preconditioning with control ischemic episodes
4 cycles of 5-minute inflation and deflation using a sphygmomanometer cuff at a pressure of 30 mmHg above the systolic value through three consecutive days
Other: Control group
Patients without CKD
Other: Preconditioning with control ischemic episodes
4 cycles of 5-minute inflation and deflation using a sphygmomanometer cuff at a pressure of 30 mmHg above the systolic value through three consecutive days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Assessment of changes of parameter: Measurement of SIRT-1 [ng/]
Time Frame: 7 days
Measurement of SIRT-1 [ng/] at the beginning and 7 days
7 days
Assessment of changes of parameter blood saturation [%].
Time Frame: 7 days
at the beginning and 7 days
7 days
Assessment of IL-6
Time Frame: 7 days
Measurement of IL-6 [ng/ml] at the beginning and 7 days.
7 days
Assessment of Blood pressure
Time Frame: 7 days
Blood pressure [mmHg] will be checked at the beginning and 7 days
7 days
Assessment of heart beat/min
Time Frame: 7 days
will be checked at the beginning and 7 days
7 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Medical University of Lodz

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

July 23, 2026

Primary Completion (Estimated)

September 1, 2026

Study Completion (Estimated)

December 31, 2026

Study Registration Dates

First Submitted

May 8, 2026

First Submitted That Met QC Criteria

August 3, 2026

First Posted (Actual)

August 4, 2026

Study Record Updates

Last Update Posted (Actual)

August 4, 2026

Last Update Submitted That Met QC Criteria

August 3, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ISP1

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe